Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.biomaterials.2005.11.008
DC FieldValue
dc.titleIn vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation
dc.contributor.authorWin, K.Y.
dc.contributor.authorFeng, S.-S.
dc.date.accessioned2014-06-17T07:43:07Z
dc.date.available2014-06-17T07:43:07Z
dc.date.issued2006-04
dc.identifier.citationWin, K.Y., Feng, S.-S. (2006-04). In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 27 (10) : 2285-2291. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biomaterials.2005.11.008
dc.identifier.issn01429612
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/64087
dc.description.abstractThis work shows a full spectrum of research on Vitamin E TPGS-emulsified Poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for paclitaxel formulation to improve its therapeutic index and to reduce the adverse effects of adjuvant Cremophor EL in its current clinical formulation of Taxol®. Paclitaxel-loaded PLGA NPs were prepared by a modified solvent extraction/evaporation technique with vitamin E TPGS as emulsifier. The formulated NPs were found in quite uniform size of ∼240 nm diameter. The in vitro drug release profile exhibited a biphasic pattern with an initial burst followed by a sustained release. In vitro HT-29 cell viability experiment demonstrated that the drug formulated in the NPs was 5.64, 5.36, 2.68, and 1.45 times more effective than that formulated in the Taxol® formulation after 24, 48, 72, 96 h treatment, respectively at 0.25 μg/mL drug concentration, which should be even better with the sustainable release feature of the NPs formulation considered. In vivo PK measurement confirmed the advantages of the NP formulation versus Taxol®. The area-under-the-curve (AUC) for 48 h for Vitamin E TPGS emulsified PLGA NP formulation of paclitaxel were found 3.0 times larger than that for the Taxol® formulation. The sustainable therapeutic time, at which the drug concentration drops below the minimum effective value, for the NP formulation could be 1.67 times longer than that for the Taxol® formulation. © 2005 Elsevier Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.biomaterials.2005.11.008
dc.sourceScopus
dc.subjectAnticancer drugs
dc.subjectBiodegradable polymers
dc.subjectChemotherapy
dc.subjectDrug delivery
dc.subjectNanoparticles
dc.subjectTaxol®
dc.typeArticle
dc.contributor.departmentCHEMICAL & BIOMOLECULAR ENGINEERING
dc.contributor.departmentBIOENGINEERING
dc.description.doi10.1016/j.biomaterials.2005.11.008
dc.description.sourcetitleBiomaterials
dc.description.volume27
dc.description.issue10
dc.description.page2285-2291
dc.description.codenBIMAD
dc.identifier.isiut000235389700013
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

135
checked on Sep 21, 2021

WEB OF SCIENCETM
Citations

105
checked on Sep 21, 2021

Page view(s)

96
checked on Sep 24, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.